The objective of this study was to compare semen quality (sperm density, progressive motility and spermia) between long-term childhood cancer survivors and a control group of males. The second objective was to correlate the semen analysis of the survivors with cancer treatment and endocrine status. The semen quality of 143 survivors (median age, 23.6 years) was compared to 200 men (median age, 27.9 years) who had not been diagnosed with cancer. The cancer-related risk factors and gonadotrophin levels were compared. Overall, 65% of the survivors had abnormal semen analysis compared to 26.5% of the controls (p < 0.0001). Survivors with nonaspermia had lower sperm density than the controls (p < 0.001). Other observed correlations were not significant. Survivors who were treated with alkylating agents were more likely to have abnormal semen analysis (p < 0.008). Follicle-stimulating hormone and luteinising hormone levels were significantly elevated (p < 0.0001) in survivors with abnormal semen analysis. The semen quality parameters, except for low sperm density, did not differ in survivors with nonaspermia compared to the controls. The risk factors included treatment with alkylating agents. Elevated gonadotrophin levels correlated with abnormal semen analysis. All cancer survivors should be made aware of the possibility of suffering from cancer treatment-related infertility.

Centre for Reproductive Genetics 2nd Faculty of Medicine Charles University and Motol University Hospital Prague Czech Republic

Department of Paediatric Haematology and Oncology 2nd Faculty of Medicine Charles University and Motol University Hospital Prague Czech Republic

Department of Paediatrics 2nd Faculty of Medicine Charles University and Motol University Hospital Prague Czech Republic

000      

00000naa a2200000 a 4500

001      

bmc21019300

003      

CZ-PrNML

005      

20210830100855.0

007      

ta

008      

210728s2021 gw f 000 0|eng||

009      

AR

024    7_

$a 10.1111/and.13853 $2 doi

035    __

$a (PubMed)33070396

040    __

$a ABA008 $b cze $d ABA008 $e AACR2

041    0_

$a eng

044    __

$a gw

100    1_

$a Kruseová, Jarmila $u Department of Paediatric Haematology and Oncology, Second Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic

245    10

$a Semen analysis and treatment risk factors in long-term survivors of childhood cancer / $c J. Kruseová, J. Černíková, M. Zámečníková, L. Hřivnová, S. Koloušková, M. Čepelová, E. Kabíčková, V. Čapek, A. Lukš, T. Eckschlager

520    9_

$a The objective of this study was to compare semen quality (sperm density, progressive motility and spermia) between long-term childhood cancer survivors and a control group of males. The second objective was to correlate the semen analysis of the survivors with cancer treatment and endocrine status. The semen quality of 143 survivors (median age, 23.6 years) was compared to 200 men (median age, 27.9 years) who had not been diagnosed with cancer. The cancer-related risk factors and gonadotrophin levels were compared. Overall, 65% of the survivors had abnormal semen analysis compared to 26.5% of the controls (p < 0.0001). Survivors with nonaspermia had lower sperm density than the controls (p < 0.001). Other observed correlations were not significant. Survivors who were treated with alkylating agents were more likely to have abnormal semen analysis (p < 0.008). Follicle-stimulating hormone and luteinising hormone levels were significantly elevated (p < 0.0001) in survivors with abnormal semen analysis. The semen quality parameters, except for low sperm density, did not differ in survivors with nonaspermia compared to the controls. The risk factors included treatment with alkylating agents. Elevated gonadotrophin levels correlated with abnormal semen analysis. All cancer survivors should be made aware of the possibility of suffering from cancer treatment-related infertility.

650    _2

$a dospělí $7 D000328

650    12

$a přežívající onkologičtí pacienti $7 D000073116

650    _2

$a dítě $7 D002648

650    _2

$a folikuly stimulující hormon $7 D005640

650    _2

$a lidé $7 D006801

650    12

$a mužská infertilita $x etiologie $7 D007248

650    _2

$a mužské pohlaví $7 D008297

650    12

$a nádory $x farmakoterapie $7 D009369

650    _2

$a rizikové faktory $7 D012307

650    _2

$a sperma $7 D012661

650    _2

$a analýza spermatu $7 D055101

650    _2

$a počet spermií $7 D013076

650    _2

$a motilita spermií $7 D013081

650    _2

$a přežívající $7 D017741

650    _2

$a mladý dospělý $7 D055815

655    _2

$a časopisecké články $7 D016428

700    1_

$a Černíková, Jelena $u Centre for Reproductive Genetics, Second Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic

700    1_

$a Zámečníková, Marina $u Centre for Reproductive Genetics, Second Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic

700    1_

$a Hřivnová, Lucie $u Department of Paediatric Haematology and Oncology, Second Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic

700    1_

$a Koloušková, Stanislava $u Department of Paediatrics, Second Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic

700    1_

$a Čepelová, Michaela $u Department of Paediatric Haematology and Oncology, Second Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic

700    1_

$a Kabíčková, Edita $u Department of Paediatric Haematology and Oncology, Second Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic

700    1_

$a Čapek, Václav $u Department of Paediatric Haematology and Oncology, Second Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic

700    1_

$a Lukš, Aleš $u Department of Paediatric Haematology and Oncology, Second Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic

700    1_

$a Eckschlager, Tomáš $u Department of Paediatric Haematology and Oncology, Second Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic

773    0_

$w MED00000345 $t Andrologia $x 1439-0272 $g Roč. 53, č. 1 (2021), s. e13853

856    41

$u https://pubmed.ncbi.nlm.nih.gov/33070396 $y Pubmed

910    __

$a ABA008 $b sig $c sign $y p $z 0

990    __

$a 20210728 $b ABA008

991    __

$a 20210830100855 $b ABA008

999    __

$a ok $b bmc $g 1690185 $s 1139746

BAS    __

$a 3

BAS    __

$a PreBMC

BMC    __

$a 2021 $b 53 $c 1 $d e13853 $e 20201018 $i 1439-0272 $m Andrologia $n Andrologia $x MED00000345

GRA    __

$a AZV NV19-03-00245 $p Ministerstvo Zdravotnictví Ceské Republiky

LZP    __

$a Pubmed-20210728